Syros pharmaceuticals, inc. (SYRS)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
Operating activities
Net loss

-75,438

-62,279

-54,010

-47,743

-

Net loss

-

-

-

-

-29,818

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization

2,521

1,604

1,527

1,273

602

Amortization of financing right-of-use asset

201

-

-

-

-

Gain on disposal of fixed assets and modification of lease

181

-

-

-

-

Loss on disposal of fixed assets

-

-

-

-4

-17

Stock-based compensation expense

9,839

6,610

4,419

4,234

3,233

Net amortization of premiums and discounts on marketable securities

949

642

102

-6

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

783

500

-131

508

390

Accounts receivable

20,158

-

-867

317

-

Other long-term assets

-

34

365

482

-

Restricted cash

-

-

-

-

413

Accounts payable

1,493

888

141

-404

2,022

Accrued expenses

-3,576

4,191

3,533

3,685

1,663

Deferred revenue

18,176

10,202

-550

-

-

Proceeds for tenant improvement incentive from landlord

7,237

-

-

-

-

Operating lease asset and liabilities

-1,365

-

-

-

-

Deferred rent and lease incentive

-

-355

-320

-284

54

Net cash provided by (used in) operating activities

-60,253

-40,315

-44,729

-40,536

-23,030

Purchases of property and equipment

12,638

1,384

821

2,322

1,176

Proceeds from the disposition of property and equipment

110

9

-

-

-

Purchases of marketable securities

108,206

96,768

41,770

25,020

-

Maturities of marketable securities

109,000

87,500

27,000

-

-

Net cash provided by (used in) investing activities

-11,734

-10,643

-15,591

-27,342

-1,176

Financing activities
Payments on financing and capital lease obligations

205

50

168

-

-

Payments on capital lease obligations

-

-

-

135

50

Proceeds from issuance of common stock through employee benefit plans

211

626

1,799

395

392

Proceeds from issuance of common stock through exercise of warrants

2

-

-

-

-

Proceeds from the issuance of common stock through employee stock purchase plan

161

-

-

-

-

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

39,813

-

Proceeds from issuance of common stock through at-the-market sales agreement, net of issuance costs

824

16,538

-

50,484

-620

Proceeds from issuance of common stock and accompanying warrants in public offerings and private placements, net of issuance costs

60,359

51,970

32,306

-

-

Proceeds from issuance of convertible preferred stock and accompanying warrants in public offering, net of issuance costs

4,638

-

-

-

-

Net cash provided by (used in) financing activities

65,990

69,084

33,937

90,557

-278

Increase (decrease) in cash, cash equivalents and restricted cash

-5,997

18,126

-26,383

22,679

-

(Decrease) increase in cash and cash equivalents

-

-

-

-

-24,484

Supplemental disclosure of cash flow information:
Cash paid for interest

72

2

9

19

18

Cash paid for tax

29

7

-

-

-

Non-cash investing and financing activities:
Conversion of convertible preferred stock into common stock

-

-

-

82,013

-

Property and equipment received but unpaid as of period end

1,565

268

143

349

1,359

Asset acquired under operating lease

16,240

-

-

-

-

Assets acquired under financing lease

1,059

28

-

-

-

Deferred financing costs incurred but unpaid as of period end

58

-

-

-

-

Assets acquired under capital lease

-

-

-

17

389

Assets acquired through lease incentive

-

-

-

-

1,612

Offering costs incurred but unpaid as of period end

23

-

13

-

1,280